Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Asthma

Interventions

DRUG: Reslizumab
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.